Erasca (ERAS) Stock Overview

A clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. More details

ERAS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Volatile share price over the past 3 months compared to the US market

Currently unprofitable and not forecast to become profitable over the next 3 years

ERAS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Erasca, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Erasca
Historical stock prices
Current Share Price	US$1.60
52 Week High	US$3.45
52 Week Low	US$1.01
Beta	1.1
1 Month Change	15.11%
3 Month Change	11.89%
1 Year Change	-32.63%
3 Year Change	-70.26%
5 Year Change	n/a
Change since IPO	-90.82%

Recent updates

Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25

Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans

Feb 07

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Oct 15

Erasca: New Focus After Restructuring, But Need More Differentiation

Sep 30

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Feb 21

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

Nov 16

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Jun 28

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Jan 20

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Oct 20

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Sep 23

Erasca adds 10% ahead of R&D Day

Sep 07

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Jul 18

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Apr 12

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Dec 28

Shareholder Returns

	ERAS	US Biotechs	US Market
7D	14.3%	4.5%	1.8%
1Y	-32.6%	-9.3%	12.6%

Return vs Industry: ERAS underperformed the US Biotechs industry which returned -9.3% over the past year.

Return vs Market: ERAS underperformed the US Market which returned 12.6% over the past year.

Price Volatility

Is ERAS's price volatile compared to industry and market?
ERAS volatility
ERAS Average Weekly Movement	16.2%
Biotechs Industry Average Movement	12.2%
Market Average Movement	7.9%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	4.1%

Stable Share Price: ERAS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ERAS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2018	103	Jonathan Lim	www.erasca.com

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors.

Erasca, Inc. Fundamentals Summary

How do Erasca's earnings and revenue compare to its market cap?
ERAS fundamental statistics
Market cap	US$453.26m
Earnings (TTM)	-US$157.60m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.9x

P/E Ratio

Is ERAS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ERAS income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$157.60m
Earnings	-US$157.60m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.56
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ERAS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/08 21:08
End of Day Share Price	2025/06/06 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Erasca, Inc. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alec Stranahan	BofA Global Research
Naureen Quibria	Capital One Securities, Inc.
Chris Shibutani	Goldman Sachs

Erasca (ERAS) Stock Overview

Risk Analysis

Erasca, Inc. Competitors

Altimmune

COMPASS Pathways

Tango Therapeutics

Zenas BioPharma

Price History & Performance

Recent News & Updates

Erasca, Inc. Announces Ind Clearance for Potential First-In-Class and Best-In-Class Pan-Kras Inhibitor Eras-4001

Price target increased by 14% to US$5.71

Erasca, Inc. Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More Than 3 Years of Projected Cash Runway

Erasca, Inc., Annual General Meeting, Jun 24, 2025

Erasca, Inc.: Carving A Different Niche In RAS Signaling

New minor risk - Share price stability

Recent updates

Erasca, Inc. Announces Ind Clearance for Potential First-In-Class and Best-In-Class Pan-Kras Inhibitor Eras-4001

Price target increased by 14% to US$5.71

Erasca, Inc. Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More Than 3 Years of Projected Cash Runway

Erasca, Inc., Annual General Meeting, Jun 24, 2025

Erasca, Inc.: Carving A Different Niche In RAS Signaling

New minor risk - Share price stability

Erasca (NASDAQ:ERAS) Is In A Good Position To Deliver On Growth Plans

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Price target decreased by 11% to US$5.00

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Erasca: New Focus After Restructuring, But Need More Differentiation

Erasca, Inc. Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

Independent Director recently bought US$182k worth of stock

Price target decreased by 11% to US$6.25

New major risk - Shareholder dilution

Erasca, Inc. has completed a Follow-on Equity Offering in the amount of $159.999999 million.

New minor risk - Shareholder dilution

Erasca, Inc., Annual General Meeting, Jun 20, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Erasca, Inc. announced that it expects to receive $45 million in funding

Is Erasca (NASDAQ:ERAS) In A Good Position To Deliver On Growth Plans?

Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

Co-Founder recently bought US$1.7m worth of stock

Price target decreased by 7.4% to US$9.00

Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

We Think Erasca (NASDAQ:ERAS) Needs To Drive Business Growth Carefully

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Co-Founder recently bought US$2.0m worth of stock

New minor risk - Share price stability

Companies Like Erasca (NASDAQ:ERAS) Are In A Position To Invest In Growth

Co-Founder recently bought US$275k worth of stock

New minor risk - Share price stability

Price target decreased by 19% to US$11.50

Erasca, Inc. Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

Erasca, Inc. Announces Promising Preliminary Data for ERAS-007 Combinations in Patients with Gastrointestinal Malignancies as Part of Two Poster Presentations That Will Be Presented At the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

Independent Director recently bought US$55k worth of stock

Price target decreased by 9.3% to US$15.57

Co-Founder recently bought US$284k worth of stock

We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth

Co-Founder recently bought US$231k worth of stock

Co-Founder recently bought US$200k worth of stock

Price target decreased to US$18.60

Erasca, Inc. Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors

Erasca forms clinical trial partnership with Pfizer for cancer therapy

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces Preliminary Data for Eras-007 and Eras-601 in Braf-Driven and Ras/Mapk-Altered Solid Tumors

Erasca adds 10% ahead of R&D Day

Erasca, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers

Erasca, Inc.(NasdaqGS:ERAS) dropped from Russell 2000 Growth Index

Erasca, Inc. Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

Erasca, Inc. Announces Key Appointments

Erasca Appoints Jean Liu to its Board of Directors

We're Not Very Worried About Erasca's (NASDAQ:ERAS) Cash Burn Rate

Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation

Erasca, Inc. Announces FDA Clearance of IND Application for Eras-801 in Glioblastoma Multiforme

Erasca, Inc. Announces First Patient Dosed in HERKULES-3, A Phase 1B/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations

Erasca, Inc. has completed an IPO in the amount of $300 million.

Shareholder Returns